Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03680560 · ClinicalTrials.gov registry record · Phase 1
Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers
A Phase 1 study, sponsored by Cogent Biosciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT03680560 is a Phase 1 study that was terminated before completion, run by Cogent Biosciences. The registered enrollment target is 6 participants.
The verdict
NCT03680560, a Phase 1 study, was terminated before completion, sponsored by Cogent Biosciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, multi-center study to assess safety and determine the recommended phase 2 dose (RP2D) of ACTR T cell product (ACTR707 or ACTR087) in combination with trastuzumab, following lymphodepleting chemotherapy in subjects with HER2-positive advanced malignancies.
Interventions
- DRUG Trastuzumab
- BIOLOGICAL ACTR T Cell Product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-03-13 |
| Est. Completion | 2020-03-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03680560
The ClinicalTrials.gov registry entry for NCT03680560 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cogent Biosciences, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Trastuzumab is the first listed.
NCT03680560 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03680560 about?
NCT03680560 is a clinical study titled "Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers". This is a Phase 1, open-label, multi-center study to assess safety and determine the recommended phase 2 dose (RP2D) of ACTR T cell product (ACTR707 or ACTR087) in combination with trastuzumab, following lymphodepleting chemotherapy in subjects with HER2-positive advanced malignancies.
What is the current status of trial NCT03680560?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2019-03-13. Estimated completion is 2020-03-12.
What interventions are being tested in trial NCT03680560?
The interventions under investigation include: Trastuzumab (DRUG), ACTR T Cell Product (BIOLOGICAL).
Who is sponsoring clinical trial NCT03680560?
This trial is sponsored by Cogent Biosciences, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.